melatonin has been researched along with Fatty Liver, Nonalcoholic in 30 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| " In a mouse NASH model with feeding of a methionine and choline-deficient (MCD) diet, MEL administration suppressed lipid accumulation and peroxidation, improved insulin sensitivity, and attenuated inflammation and fibrogenesis in the liver." | 8.31 | Melatonin alleviates diet-induced steatohepatitis by targeting multiple cell types in the liver to suppress inflammation and fibrosis. ( Ding, C; Ding, R; Dong, Z; Han, W; Jin, S; Li, D; Li, H; Ma, M; Song, M; Xu, L; Zhang, F; Zhang, O; Zhao, Y, 2023) |
| "Melatonin pleiotropically regulates physiological events and has a putative regulatory role in the circadian clock desynchrony-mediated Non-alcoholic fatty liver disease (NAFLD)." | 8.02 | Melatonin induces Nrf2-HO-1 reprogramming and corrections in hepatic core clock oscillations in Non-alcoholic fatty liver disease. ( Devkar, R; Joshi, A; Shirsath, K; Upadhyay, KK; Vohra, A, 2021) |
| "A high-fat diet (FD)-induced obesity mouse model was subjected to intermittent hypoxia/normoxia events for approximately 8 h per day using an autophagy agonist, rapamycin, or an inhibitor, 3-methyladenine (3-MA), and SRT1720, a sirtuin 1 (SIRT1) activator, or sirtinol, a SIRT1 inhibitor, with or without melatonin for a total of six successive weeks, followed by assessment of expression of autophagy-related genes and activity of serum aminotransferase as well as histological evaluation of tissue morphology." | 7.91 | Melatonin prevents chronic intermittent hypoxia-induced injury by inducing sirtuin 1-mediated autophagy in steatotic liver of mice. ( Han, Y; Jin, M; Li, GC; Liu, HG; Luo, M; Ren, J; You, ZX, 2019) |
| "Non-alcoholic fatty liver disease (NAFLD), most common chronic hepatic pathology, that occurs in the developed countries is estimated at 1/3 of the population." | 6.79 | Effects of treatment with melatonin and tryptophan on liver enzymes, parameters of fat metabolism and plasma levels of cytokines in patients with non-alcoholic fatty liver disease--14 months follow up. ( Brzozowski, T; Celinski, K; Cichoz-Lach, H; Konturek, PC; Konturek, SJ; Korolczuk, A; Slomka, M, 2014) |
| "Melatonin (Mel) is an endogenous protective molecule with antioxidant, anti-inflammatory, antiobesity, and antiaging effects." | 5.91 | Melatonin alleviates cadmium-induced nonalcoholic fatty liver disease in ducks by alleviating autophagic flow arrest via PPAR-α and reducing oxidative stress. ( Ali, W; Bian, J; Bian, Y; Gu, J; Liu, Z; Ma, Y; Sun, J; Wang, T; Yuan, Y; Zou, H, 2023) |
| "Melatonin was administered at 20 mg/kg during the last 2 weeks." | 5.72 | Melatonin Attenuates Inflammation, Oxidative Stress, and DNA Damage in Mice with Nonalcoholic Steatohepatitis Induced by a Methionine- and Choline-Deficient Diet. ( Colares, JR; da Silva, JB; Hartmann, RM; Marroni, CA; Marroni, NP; Miguel, FM; Picada, JN; Schemitt, EG, 2022) |
| "Non-alcoholic fatty liver disease (NAFLD) is the hepatic side of the metabolic syndrome." | 5.51 | Melatonin Effects on Non-Alcoholic Fatty Liver Disease Are Related to MicroRNA-34a-5p/Sirt1 Axis and Autophagy. ( De Petro, G; García-Gómez, R; Grossi, I; Lavazza, A; Monsalve, M; Patel, GA; Rezzani, R; Salvi, A; Stacchiotti, A, 2019) |
| "Obesity is a common risk factor for non-alcoholic fatty liver disease (NAFLD)." | 5.43 | Hepatic Macrosteatosis Is Partially Converted to Microsteatosis by Melatonin Supplementation in ob/ob Mice Non-Alcoholic Fatty Liver Disease. ( Aleksic, M; Favero, G; Golic, I; Korac, A; Lavazza, A; Rezzani, R; Rodella, LF; Stacchiotti, A, 2016) |
| "NAFLD was induced by HFD in C57BL/6 mice." | 5.43 | Melatonin improves non-alcoholic fatty liver disease via MAPK-JNK/P38 signaling in high-fat-diet-induced obese mice. ( Bu, L; Chen, J; Gusdon, AM; Li, L; Qu, S; Song, K; Sun, H; Wang, X, 2016) |
| "Melatonin has shown promising effects in controlling the progress of non-alcoholic fatty liver disease (NAFLD), introducing it as a possible candidate for NAFLD treatment." | 5.12 | The effects of melatonin therapy on the treatment of patients with Non-alcoholic steatohepatitis: A systematic review and Meta-analysis on clinical trial studies. ( Akhavan Rezayat, A; Akhavan Rezayat, S; Amirkhanlou, F; Bondarsahebi, Y; Ghasemi Nour, M; Hozhabrossadati, SA; Imani, B; Kiani, M, 2021) |
| "Hydrogen-rich water has a significant protective effect on OGD/R-causing HT22 cell injury, and the mechanism may be related to the inhibition of autophagy." | 4.40 | Effect of 12-week of aerobic exercise on hormones and lipid profile status in adolescent girls with polycystic ovary syndrome: A study during COVID-19. ( , 2023) |
| " In a mouse NASH model with feeding of a methionine and choline-deficient (MCD) diet, MEL administration suppressed lipid accumulation and peroxidation, improved insulin sensitivity, and attenuated inflammation and fibrogenesis in the liver." | 4.31 | Melatonin alleviates diet-induced steatohepatitis by targeting multiple cell types in the liver to suppress inflammation and fibrosis. ( Ding, C; Ding, R; Dong, Z; Han, W; Jin, S; Li, D; Li, H; Ma, M; Song, M; Xu, L; Zhang, F; Zhang, O; Zhao, Y, 2023) |
| "The preventative effect of melatonin on the development of obesity and the progression of fatty liver under a high-fat diet (HFD) has been well elucidated through previous studies." | 4.31 | Protective Effects of Melatonin in High-Fat Diet-Induced Hepatic Steatosis via Decreased Intestinal Lipid Absorption and Hepatic Cholesterol Synthesis. ( Choi, Y; Kim, AL; Kim, B; Kim, Y; Ku, H; Lee, G, 2023) |
| "Melatonin pleiotropically regulates physiological events and has a putative regulatory role in the circadian clock desynchrony-mediated Non-alcoholic fatty liver disease (NAFLD)." | 4.02 | Melatonin induces Nrf2-HO-1 reprogramming and corrections in hepatic core clock oscillations in Non-alcoholic fatty liver disease. ( Devkar, R; Joshi, A; Shirsath, K; Upadhyay, KK; Vohra, A, 2021) |
| " Liver damage, markers of glucose metabolism, inflammation, intestinal barrier function and melatonin metabolism were determined." | 3.96 | Oral Supplementation of Sodium Butyrate Attenuates the Progression of Non-Alcoholic Steatohepatitis. ( Baumann, A; Bergheim, I; Brandt, A; Burkard, M; Jin, CJ; Nier, A; Sellmann, C; Venturelli, S, 2020) |
| "A high-fat diet (FD)-induced obesity mouse model was subjected to intermittent hypoxia/normoxia events for approximately 8 h per day using an autophagy agonist, rapamycin, or an inhibitor, 3-methyladenine (3-MA), and SRT1720, a sirtuin 1 (SIRT1) activator, or sirtinol, a SIRT1 inhibitor, with or without melatonin for a total of six successive weeks, followed by assessment of expression of autophagy-related genes and activity of serum aminotransferase as well as histological evaluation of tissue morphology." | 3.91 | Melatonin prevents chronic intermittent hypoxia-induced injury by inducing sirtuin 1-mediated autophagy in steatotic liver of mice. ( Han, Y; Jin, M; Li, GC; Liu, HG; Luo, M; Ren, J; You, ZX, 2019) |
| "Non-alcoholic fatty liver disease (NAFLD), most common chronic hepatic pathology, that occurs in the developed countries is estimated at 1/3 of the population." | 2.79 | Effects of treatment with melatonin and tryptophan on liver enzymes, parameters of fat metabolism and plasma levels of cytokines in patients with non-alcoholic fatty liver disease--14 months follow up. ( Brzozowski, T; Celinski, K; Cichoz-Lach, H; Konturek, PC; Konturek, SJ; Korolczuk, A; Slomka, M, 2014) |
| "Melatonin (Mel) is an endogenous protective molecule with antioxidant, anti-inflammatory, antiobesity, and antiaging effects." | 1.91 | Melatonin alleviates cadmium-induced nonalcoholic fatty liver disease in ducks by alleviating autophagic flow arrest via PPAR-α and reducing oxidative stress. ( Ali, W; Bian, J; Bian, Y; Gu, J; Liu, Z; Ma, Y; Sun, J; Wang, T; Yuan, Y; Zou, H, 2023) |
| "Here we established a mouse model of NAFLD induced by long-term high-fat diet (HFD) feeding." | 1.91 | Melatonin Ameliorates Hepatic Ferroptosis in NAFLD by Inhibiting ER Stress via the MT2/cAMP/PKA/IRE1 Signaling Pathway. ( Cao, J; Chen, Y; Dong, Y; Guan, Q; Hu, K; Wang, Z, 2023) |
| "Melatonin (MLT) is an important pineal hormone with tremendous antioxidant and anti-inflammatory properties." | 1.91 | Melatonin targets ferroptosis through bimodal alteration of redox environment and cellular pathways in NAFLD model. ( Das, S; Manna, K; Saha, KD; Saha, M, 2023) |
| "Melatonin was administered at 20 mg/kg during the last 2 weeks." | 1.72 | Melatonin Attenuates Inflammation, Oxidative Stress, and DNA Damage in Mice with Nonalcoholic Steatohepatitis Induced by a Methionine- and Choline-Deficient Diet. ( Colares, JR; da Silva, JB; Hartmann, RM; Marroni, CA; Marroni, NP; Miguel, FM; Picada, JN; Schemitt, EG, 2022) |
| "Melatonin has been successfully tested in experimental models in mice as a drug capable of reversing steatosis." | 1.56 | Effect of Melatonin as an Antioxidant Drug to Reverse Hepatic Steatosis: Experimental Model. ( García, JJ; Gonzalo, A; Güemes, A; Martínez Soriano, B; Martínez-Beamonte, R; Navarro, AC; Osada, J; Palacios Gasós, P; Pola, G, 2020) |
| "Nonalcoholic fatty liver disease (NAFLD) is recognized globally as the leading cause of chronic liver diseases whose patients are asymptomatic and are diagnosed incidentally." | 1.56 | Melatonin regulates neurodegenerative complications associated with NAFLD via enhanced neurotransmission and cellular integrity: a correlational study. ( A Abdel Jaleel, G; A Al-Awdan, S; A H Ahmed-Farid, O; F Ahmed, R; Saleh, DO, 2020) |
| "Non-alcoholic fatty liver disease (NAFLD) is the hepatic side of the metabolic syndrome." | 1.51 | Melatonin Effects on Non-Alcoholic Fatty Liver Disease Are Related to MicroRNA-34a-5p/Sirt1 Axis and Autophagy. ( De Petro, G; García-Gómez, R; Grossi, I; Lavazza, A; Monsalve, M; Patel, GA; Rezzani, R; Salvi, A; Stacchiotti, A, 2019) |
| "Melatonin treatment significantly suppressed the ASK1 upregulation and the phosphorylation of ASK1, MKK3/6, MKK4/7, p38, and JNK." | 1.51 | Melatonin safeguards against fatty liver by antagonizing TRAFs-mediated ASK1 deubiquitination and stabilization in a β-arrestin-1 dependent manner. ( Hua, X; Huang, G; Ji, QX; Li, DJ; Li, YH; Meng, HB; Shen, FM; Tong, J; Wang, P; Zeng, FY; Zhang, GY; Zhang, WJ; Zhu, JH, 2019) |
| "Obesity is a common risk factor for non-alcoholic fatty liver disease (NAFLD)." | 1.43 | Hepatic Macrosteatosis Is Partially Converted to Microsteatosis by Melatonin Supplementation in ob/ob Mice Non-Alcoholic Fatty Liver Disease. ( Aleksic, M; Favero, G; Golic, I; Korac, A; Lavazza, A; Rezzani, R; Rodella, LF; Stacchiotti, A, 2016) |
| "NAFLD was induced by HFD in C57BL/6 mice." | 1.43 | Melatonin improves non-alcoholic fatty liver disease via MAPK-JNK/P38 signaling in high-fat-diet-induced obese mice. ( Bu, L; Chen, J; Gusdon, AM; Li, L; Qu, S; Song, K; Sun, H; Wang, X, 2016) |
| "The mechanism by which nonalcoholic fatty liver disease (NAFLD) progresses into nonalcoholic steatohepatitis (NASH) is unknown, however, the major process is oxidative stress with increased production of reactive oxygen species and excessive inflammatory cytokine generation." | 1.36 | The pilot study of 3-month course of melatonin treatment of patients with nonalcoholic steatohepatitis: effect on plasma levels of liver enzymes, lipids and melatonin. ( Bielanski, W; Brzozowski, T; Gonciarz, M; Gonciarz, Z; Konturek, PC; Konturek, SJ; Mularczyk, A, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 15 (50.00) | 24.3611 |
| 2020's | 15 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Miguel, FM | 1 |
| Picada, JN | 1 |
| da Silva, JB | 1 |
| Schemitt, EG | 1 |
| Colares, JR | 1 |
| Hartmann, RM | 1 |
| Marroni, CA | 1 |
| Marroni, NP | 1 |
| Xu, L | 1 |
| Li, H | 1 |
| Zhang, O | 1 |
| Zhang, F | 1 |
| Song, M | 1 |
| Ma, M | 1 |
| Zhao, Y | 1 |
| Ding, R | 1 |
| Li, D | 1 |
| Dong, Z | 1 |
| Jin, S | 1 |
| Han, W | 1 |
| Ding, C | 1 |
| Sun, J | 1 |
| Bian, Y | 1 |
| Ma, Y | 1 |
| Ali, W | 1 |
| Wang, T | 1 |
| Yuan, Y | 1 |
| Gu, J | 1 |
| Bian, J | 1 |
| Liu, Z | 1 |
| Zou, H | 1 |
| Guan, Q | 1 |
| Wang, Z | 1 |
| Hu, K | 1 |
| Cao, J | 1 |
| Dong, Y | 1 |
| Chen, Y | 1 |
| Ku, H | 1 |
| Kim, Y | 1 |
| Kim, AL | 1 |
| Lee, G | 1 |
| Choi, Y | 1 |
| Kim, B | 1 |
| Saha, M | 1 |
| Das, S | 1 |
| Manna, K | 1 |
| Saha, KD | 1 |
| Stacchiotti, A | 2 |
| Grossi, I | 1 |
| García-Gómez, R | 1 |
| Patel, GA | 1 |
| Salvi, A | 1 |
| Lavazza, A | 2 |
| De Petro, G | 1 |
| Monsalve, M | 1 |
| Rezzani, R | 2 |
| Li, DJ | 1 |
| Tong, J | 1 |
| Li, YH | 1 |
| Meng, HB | 1 |
| Ji, QX | 1 |
| Zhang, GY | 1 |
| Zhu, JH | 1 |
| Zhang, WJ | 1 |
| Zeng, FY | 1 |
| Huang, G | 1 |
| Hua, X | 1 |
| Shen, FM | 1 |
| Wang, P | 1 |
| Baumann, A | 1 |
| Jin, CJ | 1 |
| Brandt, A | 1 |
| Sellmann, C | 1 |
| Nier, A | 1 |
| Burkard, M | 1 |
| Venturelli, S | 1 |
| Bergheim, I | 1 |
| Martínez Soriano, B | 1 |
| Güemes, A | 1 |
| Pola, G | 1 |
| Gonzalo, A | 1 |
| Palacios Gasós, P | 1 |
| Navarro, AC | 1 |
| Martínez-Beamonte, R | 1 |
| Osada, J | 1 |
| García, JJ | 1 |
| A Abdel Jaleel, G | 1 |
| A Al-Awdan, S | 1 |
| F Ahmed, R | 1 |
| A H Ahmed-Farid, O | 1 |
| Saleh, DO | 1 |
| Mansoori, A | 1 |
| Salimi, Z | 1 |
| Hosseini, SA | 1 |
| Hormoznejad, R | 1 |
| Jafarirad, S | 2 |
| Bahrami, M | 2 |
| Asadi, M | 1 |
| Cheraghpour, M | 1 |
| Alavinejad, P | 1 |
| Asadi, F | 1 |
| Hekmatdoost, A | 1 |
| Mohammadi, M | 1 |
| Yari, Z | 1 |
| Akhavan Rezayat, A | 1 |
| Ghasemi Nour, M | 1 |
| Bondarsahebi, Y | 1 |
| Hozhabrossadati, SA | 1 |
| Amirkhanlou, F | 1 |
| Akhavan Rezayat, S | 1 |
| Kiani, M | 1 |
| Imani, B | 1 |
| Marjot, T | 1 |
| Ray, DW | 1 |
| Williams, FR | 1 |
| Tomlinson, JW | 1 |
| Armstrong, MJ | 1 |
| Joshi, A | 1 |
| Upadhyay, KK | 1 |
| Vohra, A | 1 |
| Shirsath, K | 1 |
| Devkar, R | 1 |
| Esrefoglu, M | 1 |
| Cetin, A | 1 |
| Taslidere, E | 1 |
| Elbe, H | 1 |
| Ates, B | 1 |
| Tok, OE | 1 |
| Aydin, MS | 1 |
| Zhou, H | 1 |
| Du, W | 1 |
| Li, Y | 1 |
| Shi, C | 1 |
| Hu, N | 1 |
| Ma, S | 1 |
| Wang, W | 1 |
| Ren, J | 2 |
| Mortezaee, K | 1 |
| Khanlarkhani, N | 1 |
| Zemlianitsyna, O | 1 |
| Polozova, L | 1 |
| Karachentsev, I | 1 |
| Sinaiko, V | 1 |
| Kravchun, N | 1 |
| Jin, M | 1 |
| You, ZX | 1 |
| Luo, M | 1 |
| Han, Y | 1 |
| Li, GC | 1 |
| Liu, HG | 1 |
| Ou, TH | 1 |
| Tung, YT | 1 |
| Yang, TH | 1 |
| Chien, YW | 1 |
| Celinski, K | 1 |
| Konturek, PC | 3 |
| Slomka, M | 1 |
| Cichoz-Lach, H | 1 |
| Brzozowski, T | 3 |
| Konturek, SJ | 3 |
| Korolczuk, A | 1 |
| Favero, G | 1 |
| Golic, I | 1 |
| Aleksic, M | 1 |
| Korac, A | 1 |
| Rodella, LF | 1 |
| Popov, SS | 1 |
| Pashkov, AN | 1 |
| Shul'gin, KK | 1 |
| Sun, H | 1 |
| Wang, X | 1 |
| Chen, J | 1 |
| Song, K | 1 |
| Gusdon, AM | 1 |
| Li, L | 1 |
| Bu, L | 1 |
| Qu, S | 1 |
| Gonciarz, M | 2 |
| Gonciarz, Z | 2 |
| Bielanski, W | 2 |
| Mularczyk, A | 2 |
| Zaitone, S | 1 |
| Hassan, N | 1 |
| El-Orabi, N | 1 |
| El-Awady, el-S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Impact Of Choline Administration On Oxidative Stress And Clinical Outcome Of Patients With Non-Alcoholic Fatty Liver Disease NAFLD[NCT05200156] | 100 participants (Anticipated) | Interventional | 2022-02-01 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
5 reviews available for melatonin and Fatty Liver, Nonalcoholic
| Article | Year |
|---|---|
Effect of 12-week of aerobic exercise on hormones and lipid profile status in adolescent girls with polycystic ovary syndrome: A study during COVID-19.
Topics: Actin Cytoskeleton; Actins; Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adenosine Triphosp | 2023 |
The effect of melatonin supplementation on liver indices in patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis of randomized clinical trials.
Topics: Alanine Transaminase; Alkaline Phosphatase; Aspartate Aminotransferases; Biomarkers; gamma-Glutamylt | 2020 |
The effects of melatonin therapy on the treatment of patients with Non-alcoholic steatohepatitis: A systematic review and Meta-analysis on clinical trial studies.
Topics: Alanine Transaminase; Alkaline Phosphatase; Aspartate Aminotransferases; gamma-Glutamyltransferase; | 2021 |
Sleep and liver disease: a bidirectional relationship.
Topics: Body Temperature Regulation; Case-Control Studies; Chronic Disease; Cost of Illness; Disease Progres | 2021 |
Melatonin application in targeting oxidative-induced liver injuries: A review.
Topics: Animals; Antioxidants; Carcinoma, Hepatocellular; Chemical and Drug Induced Liver Injury; Humans; Li | 2018 |
4 trials available for melatonin and Fatty Liver, Nonalcoholic
| Article | Year |
|---|---|
Effect of 12-week of aerobic exercise on hormones and lipid profile status in adolescent girls with polycystic ovary syndrome: A study during COVID-19.
Topics: Actin Cytoskeleton; Actins; Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adenosine Triphosp | 2023 |
The effect of melatonin on treatment of patients with non-alcoholic fatty liver disease: a randomized double blind clinical trial.
Topics: Adult; Antioxidants; Biomarkers; Blood Pressure; Body Weights and Measures; Double-Blind Method; Fem | 2020 |
Effects of treatment with melatonin and tryptophan on liver enzymes, parameters of fat metabolism and plasma levels of cytokines in patients with non-alcoholic fatty liver disease--14 months follow up.
Topics: Adult; Cholesterol, LDL; Cytokines; Fatty Liver; Female; gamma-Glutamyltransferase; Humans; Lipid Me | 2014 |
The effects of long-term melatonin treatment on plasma liver enzymes levels and plasma concentrations of lipids and melatonin in patients with nonalcoholic steatohepatitis: a pilot study.
Topics: Adult; Alanine Transaminase; Alkaline Phosphatase; Aspartate Aminotransferases; Blood Glucose; Chole | 2012 |
22 other studies available for melatonin and Fatty Liver, Nonalcoholic
| Article | Year |
|---|---|
Melatonin Attenuates Inflammation, Oxidative Stress, and DNA Damage in Mice with Nonalcoholic Steatohepatitis Induced by a Methionine- and Choline-Deficient Diet.
Topics: Alanine Transaminase; Animals; Anti-Inflammatory Agents; Antioxidants; Aspartate Aminotransferases; | 2022 |
Melatonin alleviates diet-induced steatohepatitis by targeting multiple cell types in the liver to suppress inflammation and fibrosis.
Topics: Animals; Choline; Diet; Disease Models, Animal; Humans; Inflammation; Lipids; Liver; Liver Cirrhosis | 2023 |
Melatonin alleviates cadmium-induced nonalcoholic fatty liver disease in ducks by alleviating autophagic flow arrest via PPAR-α and reducing oxidative stress.
Topics: Animals; Autophagy; Cadmium; Chickens; Ducks; Fatty Acids; Lipids; Liver; Melatonin; Non-alcoholic F | 2023 |
Melatonin Ameliorates Hepatic Ferroptosis in NAFLD by Inhibiting ER Stress via the MT2/cAMP/PKA/IRE1 Signaling Pathway.
Topics: Animals; Diet, High-Fat; Endoplasmic Reticulum Stress; Ferroptosis; Liver; Melatonin; Mice; Mice, In | 2023 |
Protective Effects of Melatonin in High-Fat Diet-Induced Hepatic Steatosis via Decreased Intestinal Lipid Absorption and Hepatic Cholesterol Synthesis.
Topics: Animals; Cholesterol; Cytokines; Diet, High-Fat; Lipids; Melatonin; Mice; Non-alcoholic Fatty Liver | 2023 |
Melatonin targets ferroptosis through bimodal alteration of redox environment and cellular pathways in NAFLD model.
Topics: Animals; Ferroptosis; Lipid Peroxides; Melatonin; Mice; Mice, Inbred C57BL; NF-E2-Related Factor 2; | 2023 |
Melatonin Effects on Non-Alcoholic Fatty Liver Disease Are Related to MicroRNA-34a-5p/Sirt1 Axis and Autophagy.
Topics: Animals; Autophagy; Diet, High-Fat; Inflammation; Insulin Resistance; Liver; Male; Melatonin; Mice; | 2019 |
Melatonin safeguards against fatty liver by antagonizing TRAFs-mediated ASK1 deubiquitination and stabilization in a β-arrestin-1 dependent manner.
Topics: Animals; beta-Arrestin 1; Dietary Fats; Enzyme Stability; Male; MAP Kinase Kinase Kinase 5; Melatoni | 2019 |
Oral Supplementation of Sodium Butyrate Attenuates the Progression of Non-Alcoholic Steatohepatitis.
Topics: Animals; Butyric Acid; Cholesterol, Dietary; Diet, High-Fat; Dietary Supplements; Disease Models, An | 2020 |
Effect of Melatonin as an Antioxidant Drug to Reverse Hepatic Steatosis: Experimental Model.
Topics: Animals; Antioxidants; Diet, High-Fat; Disease Models, Animal; Lipid Metabolism; Liver; Melatonin; N | 2020 |
Melatonin regulates neurodegenerative complications associated with NAFLD via enhanced neurotransmission and cellular integrity: a correlational study.
Topics: Animals; Antioxidants; Brain; Cellular Microenvironment; Diet, High-Fat; Liver; Male; Melatonin; Neu | 2020 |
Melatonin induces Nrf2-HO-1 reprogramming and corrections in hepatic core clock oscillations in Non-alcoholic fatty liver disease.
Topics: Animals; Circadian Clocks; Circadian Rhythm; Heme Oxygenase-1; Hep G2 Cells; Humans; Liver; Male; Me | 2021 |
Therapeutic effects of melatonin and quercetin in improvement of hepatic steatosis in rats through supression of oxidative damage.
Topics: Animals; Antioxidants; Carbon Tetrachloride; Female; Hemorrhage; Inflammation; Liver; Liver Cirrhosi | 2017 |
Effects of melatonin on fatty liver disease: The role of NR4A1/DNA-PKcs/p53 pathway, mitochondrial fission, and mitophagy.
Topics: Dynamins; GTP Phosphohydrolases; Humans; Melatonin; Microtubule-Associated Proteins; Mitochondrial P | 2018 |
FEATURES OF EXCRETION OF MELATONIN IN URINE IN PATIENTS WITH TYPE 2 DIABETES MELLITUS AND NON-ALCOHOLIC FATTY LIVER DISEASE WITH MANIFESTATIONS OF FIBROSIS AND ITS RELATIONSHIP WITH CERTAIN METABOLIC AND IMMUNOLOGICAL INDICATORS.
Topics: Adolescent; Adult; Albuminuria; Biomarkers; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; | 2018 |
Melatonin prevents chronic intermittent hypoxia-induced injury by inducing sirtuin 1-mediated autophagy in steatotic liver of mice.
Topics: Animals; Autophagy; Cardiotonic Agents; Disease Models, Animal; Dose-Response Relationship, Drug; Fe | 2019 |
Melatonin Improves Fatty Liver Syndrome by Inhibiting the Lipogenesis Pathway in Hamsters with High-Fat Diet-Induced Hyperlipidemia.
Topics: Acetyl-CoA Carboxylase; Animals; Antioxidants; Carnitine O-Palmitoyltransferase; Cholesterol; Choles | 2019 |
Hepatic Macrosteatosis Is Partially Converted to Microsteatosis by Melatonin Supplementation in ob/ob Mice Non-Alcoholic Fatty Liver Disease.
Topics: Animals; Antioxidants; beta Catenin; Calnexin; Disease Models, Animal; Disease Progression; Endoplas | 2016 |
[EFFECTS OF MELATONIN ON THE ACONITATE HYDRATASE ACTIVITY, CONTENT OF LIPID PEROXIDATION PRODUCTS AND SOME NON-ENZYMATIC ANTIOXIDANTS IN THE BLOOD OF PATIENTS WITH TYPE 2 DIABETES MELLITUS COMPLICATED BY STEATOHEPATITIS].
Topics: Aconitate Hydratase; Adult; Aged; alpha-Tocopherol; Antioxidants; Citric Acid; Diabetes Mellitus, Ty | 2015 |
Melatonin improves non-alcoholic fatty liver disease via MAPK-JNK/P38 signaling in high-fat-diet-induced obese mice.
Topics: Administration, Oral; Animals; Cytokines; Diet, High-Fat; Down-Regulation; Liver; Male; MAP Kinase S | 2016 |
The pilot study of 3-month course of melatonin treatment of patients with nonalcoholic steatohepatitis: effect on plasma levels of liver enzymes, lipids and melatonin.
Topics: Alanine Transaminase; Antioxidants; Aspartate Aminotransferases; Blood Glucose; Cholesterol; Fatty L | 2010 |
Pentoxifylline and melatonin in combination with pioglitazone ameliorate experimental non-alcoholic fatty liver disease.
Topics: Alanine Transaminase; Animals; Antioxidants; Aspartate Aminotransferases; Biomarkers; Body Weight; C | 2011 |